Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered plant allergens with reduced anaphylactic activity.

M B Singh1, N de Weerd, P L Bhalla

  • 1Plant Molecular Biology and Biotechnology Laboratory, Institute of Land and Food Resources, University of Melbourne, Parkville, Vic., Australia.

International Archives of Allergy and Immunology
|July 8, 1999
PubMed
Summary

Allergen immunotherapy uses purified allergens to retrain the immune system. Genetically engineered allergens with reduced allergic reactions offer a safer approach to allergy immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Tele-Neuromuscular Clinic on the Accessibility of Care for Patients with Inherited Neuromuscular Disorders during COVID-19 Pandemic in India.

Annals of Indian Academy of Neurology·2022
Same author

Cerebral Venous Sinus Thrombosis Presenting with Features of Raised Intracranial Tension and En Plaque Meningeal Thickening; A Case Report.

Annals of Indian Academy of Neurology·2022
Same author

Male gametes and fertilization in angiosperms.

The New phytologist·2021
Same author

Steroid Responsive Acute Isolated Ophthalmoplegia: A Rare Presentation of Anti-Gq1b Antibodies Syndrome.

Annals of Indian Academy of Neurology·2021
Same author

Systemic lupus erythematosus presenting with holocord myelitis.

Journal of postgraduate medicine·2020
Same author

Delayed bilateral internal carotid artery dissection following motor vehicle accident: time to make its screening a part of trauma protocol?

QJM : monthly journal of the Association of Physicians·2020

Area of Science:

  • Immunology
  • Biotechnology
  • Allergology

Background:

  • Allergy immunotherapy involves administering increasing allergen doses to induce non-responsiveness.
  • Current immunotherapy relies on heterogeneous natural extracts with undefined components.
  • Recombinant DNA technology allows for pure, well-characterized allergens but carries risks of anaphylaxis.

Purpose of the Study:

  • To explore the use of genetically engineered recombinant allergens with reduced anaphylactic activity for improved allergy immunotherapy.
  • To investigate the potential of modified allergens in enhancing the safety and efficacy of allergen-specific immunotherapy.

Main Methods:

  • Utilizing recombinant DNA technology to produce purified allergens.
  • Employing site-directed mutagenesis to create allergen variants with reduced IgE reactivity.

Related Experiment Videos

  • Assessing retained T-cell reactivity in modified allergens.

    • Main Results:

    • Genetically engineered variants of major grass, birch, and oilseed rape allergens were successfully produced.
    • These modified allergens demonstrated reduced IgE reactivity, indicating lower anaphylactic potential.
    • Crucially, T-cell reactivity was retained, suggesting preserved therapeutic immune modulation.

    Conclusions:

    • Genetically engineered recombinant allergens with reduced anaphylactic potential are promising for safer immunotherapy.
    • Modified allergens offer a novel strategy for more effective and safer allergen-specific immunotherapy.
    • This approach addresses the limitations of traditional immunotherapy and the risks associated with pure recombinant allergens.